January 16, 2012

HER2 proteins do not predict breast cancer patient’s outcome after Herceptin treatment


Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth… "This study debunks the hopeful notion, strongly felt in the breast cancer community, that measuring levels of a number of different proteins in the HER2 family could help oncologists better tailor their use of Herceptin," says the study's senior investigator, Edith Perez, M.D., director of Mayo Clinic's Breast Program in Florida.

News Medical, 12/2011 Additional coverage: MedIndia, Emax Health

Tags: Cancer, Edith Perez, Herceptin, M.D., Mayo Clinic Jacksonville

Please sign in or register to post a reply.
Contact Us · Privacy Policy